Infection Related to Implantable Central Venous Access Devices in Cancer Patients: Epidemiology and Risk Factors

Carregando...
Imagem de Miniatura
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
UNIV CHICAGO PRESS
Citação
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, v.34, n.7, p.671-677, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE. To describe the epidemiology of infections related to the use of implantable central venous access devices (CVADs) in cancer patients and to evaluate measures aimed at reducing the rates of such infections. DESIGN. Prospective cohort study. SETTING. Referral hospital for cancer in Sao Paulo, Brazil. PATIENTS. We prospectively evaluated all implantable CVADs employed between January 2009 and December 2011. Inpatients and outpatients were followed until catheter removal, transfer to another facility, or death. METHODS. Outcome measures were bloodstream infection and pocket infection. We also evaluated the effects that the creation of a multidisciplinary team for CVAD care, avoiding in-hospital implantation of CVADs, and limiting CVAD insertion in neutropenic patients have on the rates of such infections. RESULTS. During the study period, 966 CVADs (mostly venous ports) were implanted in 933 patients, for a combined total of 243,792 catheter-days. We identified 184 episodes of infection: 154 (84%) were bloodstream infections, 21 (11%) were pocket infections, and 9 (5%) were surgical site infections. During the study period, the rate of CVAD-related infection dropped from 2.2 to 0.24 per 1,000 catheter-days (P < .001). Multivariate analysis revealed that relevant risk factors for such infection include surgical reintervention, implantation in a neutropenic patient, in-hospital implantation, use of a cuffed catheter, and nonchemotherapy indication for catheter use. CONCLUSIONS. Establishing a multidisciplinary team specifically focused on CVAD care, together with systematic reporting of infections, appears to reduce the rates of infection related to the use of these devices.
Palavras-chave
Referências
  1. Adler A, 2006, J HOSP INFECT, V62, P358, DOI 10.1016/j.jhin.2005.08.019
  2. Bass J, 2011, J PEDIATR SURG, V46, P942, DOI 10.1016/j.jpedsurg.2011.02.034
  3. Beckers MMJ, 2010, THROMB RES, V125, P318, DOI 10.1016/j.thromres.2009.06.008
  4. Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F
  5. Chang YF, 2013, PALLIATIVE MED, V27, P185, DOI 10.1177/0269216311428777
  6. Crisinel M, 2009, MED MALADIES INFECT, V39, P252, DOI 10.1016/j.medmal.2008.11.004
  7. Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901
  8. Delgado-Rodriguez M, 2001, AM J INFECT CONTROL, V29, P289, DOI 10.1067/mic.2001.114625
  9. Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
  10. Harron K, 2011, INTENS CARE MED, V37, P1641, DOI 10.1007/s00134-011-2343-9
  11. Hsieh CC, 2009, WORLD J GASTROENTERO, V15, P4709, DOI 10.3748/wjg.15.4709
  12. Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376
  13. Nam SH, 2010, PEDIATR BLOOD CANCER, V54, P546, DOI 10.1002/pbc.22286
  14. Nouwen JL, 1999, J CLIN ONCOL, V17, P1304
  15. O'Grady NP, 2011, CLIN INFECT DIS, V52, P1087, DOI 10.1093/cid/cir138
  16. PEGUES D, 1992, J SURG ONCOL, V49, P156, DOI 10.1002/jso.2930490306
  17. Penel N, 2007, CANCER, V110, P1586, DOI 10.1002/cncr.22942
  18. Petrosillo N, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-34
  19. Ramritu P, 2008, J ADV NURS, V62, P3, DOI 10.1111/j.1365-2648.2007.04564.x
  20. Schneeberger PM, 2002, J HOSP INFECT, V51, P179, DOI 10.1053/jhin.2002.1256
  21. Sotir MJ, 1999, INFECT CONT HOSP EP, V20, P187, DOI 10.1086/501609
  22. Tomlinson D, 2011, CLIN INFECT DIS, V53, P697, DOI 10.1093/cid/cir523
  23. Toure A, 2012, AM J INFECT CONTROL, V40, P935, DOI 10.1016/j.ajic.2012.01.024
  24. Wolosker N, 2004, SAO PAULO MED J, V4, P147
  25. World Health Organization (WHO), 2009, WHO GUID SAF SURG 20
  26. Yoshida J, 2011, AM J INFECT CONTROL, V39, pE39, DOI 10.1016/j.ajic.2010.11.013